UroGen Pharma Ltd. (URGN) shareholders
Close on Nov 18, 2026Market cap $1.46BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Roderick Wong, M.D Joint filing with RTW Investments, LP (9.99%) | 4,930,204 | 9.99% | 13G (passive) amendment | Sep 30, 2024 |
| Paradigm BioCapital Advisors LP Joint filing with Paradigm BioCapital Advisors GP LLC (9.00%), Senai Asefaw, M.D. (9.00%) and 1 more | 4,216,084 | 9.00% | 13G (passive) amendment | Sep 30, 2025 |
| The Toronto-Dominion Bank | 3,269,957 | 6.70% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 3,058,648 | 6.30% | 13G (passive) amendment | Sep 30, 2026 |
| Robert Atchinson Joint filing with Adage Capital Management, L.P. (6.94%), Phillip Gross (6.94%) | 2,928,086 | 6.94% | 13G (passive) amendment | Dec 31, 2024 |
| Morgan Stanley | 2,488,299 | 5.40% | 13G (passive) | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of URGN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Rtw Investments, LP | 4,543,895 | 9.30% | $167.22M | – | 1.43% |
| BlackRock, Inc. | 3,201,461 | 6.55% | $117.81M | +355,894 | 0.00% |
| Morgan Stanley | 2,576,363 | 5.27% | $94.81M | +16,325 | 0.01% |
| Kynam Capital Management, LP | 2,434,207 | 4.98% | $89.58M | +186,814 | 4.95% |
| Jefferies Financial Group Inc. | 2,199,652 | 4.50% | $80.95M | – | 0.53% |
| SG Americas Securities, LLC | 2,052,906 | 4.20% | $75.55M | +395,060 | 0.04% |
| American Century Companies Inc | 1,685,719 | 3.45% | $62.03M | +48,149 | 0.03% |
| Acorn Capital Advisors, LLC | 1,673,420 | 3.42% | $61.58M | – | 16.80% |
| Point72 Asset Management, L.P. | 1,525,549 | 3.12% | $56.14M | New | 0.06% |
| Frontier Capital Management Co LLC | 1,508,547 | 3.09% | $55.51M | +194,435 | 0.52% |
| Opaleye Management Inc. | 1,439,996 | 2.95% | $52.99M | +9,996 | 4.80% |
| Silverarc Capital Management, LLC | 1,301,979 | 2.66% | $47.91M | −201,066 | 4.98% |
| Menora Mivtachim Holdings Ltd. | 1,152,531 | 2.36% | $42.41M | – | 0.17% |
| D. E. Shaw & Co., Inc. | 1,145,819 | 2.34% | $42.17M | +122,660 | 0.02% |
| State Street Corp | 1,003,071 | 2.05% | $36.91M | +128,895 | 0.00% |
| Mpm Bioimpact LLC | 933,415 | 1.91% | $34.35M | −10,388 | 2.09% |
| Soleus Capital Management, L.P. | 829,810 | 1.70% | $30.54M | +102,810 | 1.05% |
| Goldman Sachs Group Inc | 819,834 | 1.68% | $30.17M | +221,306 | 0.00% |
| Migdal Insurance & Financial Holdings Ltd. | 770,909 | 1.58% | $28.37M | – | 0.18% |
| Orbimed Advisors LLC | 676,187 | 1.38% | $24.88M | −199,300 | 0.46% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 189 | 42M | 86.8% | 40 / 61 | 54 / 21 | 5M | 9M |
| Q1 2026 | 173 | 46M | 95.0% | 33 / 52 | 47 / 25 | 11M | 8M |
| Q4 2025 | 167 | 44M | 89.4% | 30 / 53 | 52 / 24 | 9M | 10M |
| Q3 2025 | 161 | 45M | 91.1% | 34 / 48 | 47 / 22 | 12M | 8M |
| Q2 2025 | 150 | 41M | 83.2% | 40 / 46 | 40 / 30 | 16M | 17M |
| Q1 2025 | 140 | 42M | 85.2% | 20 / 46 | 48 / 17 | 10M | 4M |
| Q4 2024 | 138 | 36M | 74.2% | 30 / 42 | 39 / 20 | 10M | 9M |
| Q3 2024 | 128 | 35M | 72.0% | 26 / 50 | 29 / 12 | 7M | 8M |
| Q2 2024 | 115 | 38M | 78.2% | 23 / 55 | 20 / 19 | 13M | 2M |
| Q1 2024 | 112 | 28M | 57.2% | 20 / 32 | 35 / 13 | 7M | 1M |
| Q4 2023 | 105 | 22M | 44.8% | 16 / 50 | 19 / 12 | 5M | 1M |
| Q3 2023 | 101 | 18M | 36.3% | 24 / 35 | 22 / 8 | 7M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
50 funds held URGN in Q2 2026, 25% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of URGN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Small Cap Growth Fund | 874,981 | 1.79% | $33.46M | 0.60% | Jul 31, 2026 |
| Vanguard Russell 2000 Index Fund | 206,762 | 0.42% | $5.82M | 0.03% | May 31, 2026 |
| Vanguard Explorer Value Fund | 189,986 | 0.39% | $5.34M | 0.43% | May 31, 2026 |
| Vanguard Health Care Index Fund | 118,284 | 0.24% | $3.33M | 0.02% | May 31, 2026 |
| Clearwater Select Equity Fund | 61,274 | 0.13% | $2.25M | 0.44% | Jun 30, 2026 |
| Tema Oncology ETF | 58,518 | 0.12% | $1.65M | 0.93% | May 31, 2026 |
| Nuveen Small Cap Blend Index Fund | 52,750 | 0.11% | $2.02M | 0.05% | Jul 31, 2026 |
| Amplify BlueStar Israel Technology ETF | 43,319 | 0.09% | $1.59M | 1.33% | Jun 30, 2026 |
| M Capital Appreciation Fund | 36,861 | 0.08% | $1.36M | 0.43% | Jun 30, 2026 |
| Nuveen Equity Index Fund | 34,807 | 0.07% | $1.33M | 0.00% | Jul 31, 2026 |
| Vanguard U.S. Momentum Factor ETF | 33,104 | 0.07% | $931.22K | 0.05% | May 31, 2026 |
| Vanguard Russell 2000 Growth Index Fund | 31,194 | 0.06% | $877.49K | 0.05% | May 31, 2026 |
| Small Cap Index Fund | 21,528 | 0.04% | $792.23K | 0.05% | Jun 30, 2026 |
| Global X Russell 2000 ETF | 20,398 | 0.04% | $780.02K | 0.05% | Jul 31, 2026 |
| Global Small Cap Fund | 17,772 | 0.04% | $499.93K | 0.77% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Chris Degnan | Chief Financial Officer | 4,561 | 0.01% | Oct 9, 2026 |
| Mark Schoenberg | Chief Medical Officer | 67,849 | 0.14% | Sep 9, 2026 |
| Jason Drew Smith | General Counsel | 53,141 | 0.11% | Sep 9, 2026 |
| Elizabeth A. Barrett | Chief Executive Officer | 313,358 | 0.64% | Feb 19, 2026 |
| James A. Robinson Jr. | Director | 8,000 | 0.02% | Aug 28, 2026 |
| Daniel George Wildman | Director | 2,000 | 0.00% | Jun 24, 2026 |
| Leana Wen | Director | 2,000 | 0.00% | Jun 24, 2026 |
| Cynthia M. Butitta | Director | 2,000 | 0.00% | Jun 24, 2026 |
| Arie Belldegrun | Director | 408,693 | 0.84% | Jun 24, 2026 |
| Stuart Holden | Director | 2,000 | 0.00% | Jun 24, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Chris Degnan Chief Financial Officer | Oct 8, 2026 | Sale | −2,202 | $36.69 | $80.79K | 4,561 |
| Chris Degnan Chief Financial Officer | Oct 8, 2026 | Option exercise | +4,483 | – | – | 6,763 |
| Mark Schoenberg Chief Medical Officer | Sep 8, 2026 | Sale | −871 | $42.92 | $37.38K | 59,882 |
| Jason Drew Smith General Counsel | Sep 8, 2026 | Sale | −1,519 | $42.54 | $64.62K | 53,141 |
| Mark Schoenberg Chief Medical Officer | Sep 7, 2026 | Option exercise | +1,667 | – | – | 60,753 |
| Jason Drew Smith General Counsel | Sep 7, 2026 | Option exercise | +3,334 | – | – | 54,660 |
| James A. Robinson Jr. Director | Aug 26, 2026 | Option exercise | +2,000 | – | – | 8,000 |
| Mark Schoenberg Chief Medical Officer | Aug 20, 2026 | Sale | −60,677 | $47.05 | $2.85M | 59,086 |
| Mark Schoenberg Chief Medical Officer | Jul 9, 2026 | Sale(10b5-1 plan) | −10,000 | $40.00 | $400.00K | 119,763 |
| Mark Schoenberg Chief Medical Officer | Jun 22, 2026 | Sale(10b5-1 plan) | −10,000 | $35.01 | $350.10K | 129,763 |
| Mark Schoenberg Chief Medical Officer | Jun 8, 2026 | Option exercise | +10,000 | – | – | 144,985 |
| Mark Schoenberg Chief Medical Officer | Jun 8, 2026 | Sale | −5,222 | $27.30 | $142.56K | 139,763 |
| James A. Robinson Jr. Director | May 26, 2026 | Option exercise | +2,000 | – | – | 6,000 |
| Mark Schoenberg Chief Medical Officer | May 8, 2026 | Sale(10b5-1 plan) | −10,000 | $30.00 | $300.00K | 134,985 |
| Jason Drew Smith General Counsel | Feb 3, 2026 | Sale | −2,654 | $19.69 | $52.26K | 52,934 |
| Jason Drew Smith General Counsel | Feb 3, 2026 | Sale | −1,608 | $19.69 | $31.66K | 51,326 |
| Jason Drew Smith General Counsel | Feb 3, 2026 | Sale | −3,217 | $19.69 | $63.34K | 55,588 |
| Mark Schoenberg Chief Medical Officer | Feb 3, 2026 | Sale | −1,844 | $19.69 | $36.31K | 150,514 |
| Mark Schoenberg Chief Medical Officer | Feb 3, 2026 | Sale | −3,686 | $19.69 | $72.58K | 144,985 |
| Mark Schoenberg Chief Medical Officer | Feb 3, 2026 | Sale | −1,843 | $19.69 | $36.29K | 148,671 |
| Jason Drew Smith General Counsel | Jan 31, 2026 | Option exercise | +5,500 | – | – | 55,472 |
| Jason Drew Smith General Counsel | Jan 31, 2026 | Option exercise | +6,667 | – | – | 49,972 |
| Jason Drew Smith General Counsel | Jan 31, 2026 | Option exercise | +3,333 | – | – | 58,805 |
| Mark Schoenberg Chief Medical Officer | Jan 31, 2026 | Option exercise | +6,666 | – | – | 152,358 |
| Mark Schoenberg Chief Medical Officer | Jan 31, 2026 | Option exercise | +3,333 | – | – | 145,692 |
| Mark Schoenberg Chief Medical Officer | Jan 31, 2026 | Option exercise | +3,334 | – | – | 142,359 |
| James A. Robinson Jr. Director | Nov 26, 2025 | Option exercise | +2,000 | – | – | 2,000 |
| Cynthia M. Butitta Director | Nov 26, 2025 | Option exercise | +2,000 | – | – | 2,000 |
| Leana Wen Director | Nov 26, 2025 | Option exercise | +2,000 | – | – | 2,000 |
| Daniel George Wildman Director | Nov 26, 2025 | Option exercise | +2,000 | – | – | 2,000 |
| Stuart Holden Director | Nov 26, 2025 | Option exercise | +2,000 | – | – | 2,000 |
| Mark Schoenberg Chief Medical Officer | Nov 19, 2025 | Sale(10b5-1 plan) | −10,000 | $25.00 | $250.00K | 139,025 |
| Chris Degnan Chief Financial Officer | Oct 8, 2025 | Sale | −2,203 | $16.85 | $37.12K | 2,280 |
| Chris Degnan Chief Financial Officer | Oct 8, 2025 | Option exercise | +4,483 | – | – | 4,483 |
| Jason Drew Smith General Counsel | Sep 8, 2025 | Sale | −1,520 | $19.11 | $29.05K | 43,305 |
| Mark Schoenberg Chief Medical Officer | Sep 8, 2025 | Sale | −871 | $19.11 | $16.64K | 149,025 |
| Jason Drew Smith General Counsel | Sep 7, 2025 | Option exercise | +3,333 | – | – | 44,825 |
| Mark Schoenberg Chief Medical Officer | Sep 7, 2025 | Option exercise | +1,667 | – | – | 149,896 |
| Mark Schoenberg Chief Medical Officer | Aug 11, 2025 | Sale | −10,000 | $17.69 | $176.90K | 148,229 |
| Jason Drew Smith General Counsel | Jul 28, 2025 | Option exercise | +16,500 | – | – | 49,014 |
| Jason Drew Smith General Counsel | Jul 28, 2025 | Sale | −7,522 | $19.14 | $143.97K | 41,492 |
| Mark Schoenberg Chief Medical Officer | Jul 28, 2025 | Option exercise | +10,000 | – | – | 163,378 |
| Mark Schoenberg Chief Medical Officer | Jul 28, 2025 | Sale | −5,149 | $19.14 | $98.55K | 158,229 |
| Mark Schoenberg Chief Medical Officer | Jun 9, 2025 | Sale | −5,162 | $7.37 | $38.04K | 153,378 |
| Mark Schoenberg Chief Medical Officer | Jun 8, 2025 | Option exercise | +10,000 | – | – | 158,540 |
| James A. Robinson Jr. Director | Feb 26, 2025 | Option exercise | +2,000 | – | – | 4,000 |
| Mark Schoenberg Chief Medical Officer | Jan 31, 2025 | Sale | −1,896 | $11.14 | $21.12K | 148,540 |
| Mark Schoenberg Chief Medical Officer | Jan 31, 2025 | Option exercise | +1,334 | – | – | 146,425 |
| Mark Schoenberg Chief Medical Officer | Jan 31, 2025 | Sale | −759 | $11.14 | $8.46K | 145,666 |
| Mark Schoenberg Chief Medical Officer | Jan 31, 2025 | Option exercise | +3,333 | – | – | 148,999 |
| Mark Schoenberg Chief Medical Officer | Jan 31, 2025 | Sale | −1,896 | $11.14 | $21.12K | 147,103 |
| Mark Schoenberg Chief Medical Officer | Jan 31, 2025 | Option exercise | +3,333 | – | – | 150,436 |
| Jason Drew Smith General Counsel | Jan 31, 2025 | Option exercise | +5,500 | – | – | 35,281 |
| Jason Drew Smith General Counsel | Jan 31, 2025 | Sale | −3,354 | $11.14 | $37.36K | 29,781 |
| Jason Drew Smith General Counsel | Jan 31, 2025 | Sale | −1,258 | $11.14 | $14.01K | 26,468 |
| Jason Drew Smith General Counsel | Jan 31, 2025 | Option exercise | +2,500 | – | – | 27,726 |
| Jason Drew Smith General Counsel | Jan 31, 2025 | Option exercise | +6,667 | – | – | 33,135 |
| Jason Drew Smith General Counsel | Jan 31, 2025 | Sale | −2,767 | $11.14 | $30.82K | 32,514 |
| Dong Kim Chief Financial Officer | Sep 9, 2024 | Option exercise | +2,500 | – | – | 37,753 |
| Mark Schoenberg Chief Medical Officer | Sep 9, 2024 | Sale | −859 | $13.08 | $11.24K | 145,091 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of UroGen Pharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 39,984 shares on Oct 13, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Christopher Degnan Officer | Oct 9, 2026 | 2,202 | $89.62K | Oct 8, 2026 | Shares issued upon vesting of RSUs |
| Mark Schoenberg Officer | Sep 9, 2026 | 871 | $38.40K | Sep 8, 2026 | Shares issued upon vesting of RSUs |
| Jason Drew Smith Officer | Sep 9, 2026 | 1,519 | $66.97K | Sep 8, 2026 | Shares issued upon vesting of RSUs |
| Mark Schoenberg Officer | Aug 20, 2026 | 60,677 | $2.89M | Aug 20, 2026 | STOCK OPTION EXERCISE |
| Mark Schoenberg Officer | Jul 9, 2026 | 10,000 | $400.01K | Jul 9, 2026 | STOCK OPTION EXERCISE |
| Mark Schoenberg Officer | Jun 22, 2026 | 10,000 | $350.14K | Jun 22, 2026 | STOCK OPTION EXERCISE |
| Mark Schoenberg Officer | Jun 9, 2026 | 5,222 | $140.21K | Jun 8, 2026 | Shares issued upon vesting of RSUs |
| Mark Schoenberg Officer | May 8, 2026 | 10,000 | $300.05K | May 8, 2026 | OPTION EXERCISE |
| Mark Schoenberg Officer | Feb 3, 2026 | 13,333 | $261.46K | Feb 2, 2026 | RSU |
| Mark Schoenberg Officer | Nov 19, 2025 | 10,000 | $250.01K | Nov 19, 2025 | STOCK OPTION EXERCISE |
| Mark Schoenberg Officer | Sep 9, 2025 | 871 | $16.44K | Sep 8, 2025 | RSU |
| Jason Drew Smith Officer | Sep 9, 2025 | 1,520 | $28.70K | Sep 8, 2025 | RSU |
| Mark Schoenberg Officer | Jul 29, 2025 | 5,149 | $97.57K | Jul 28, 2025 | Restricted Stock Units |
| Jason Drew Smith Officer | Jul 29, 2025 | 7,522 | $142.54K | Jul 28, 2025 | Restricted Stock Units |
| Mark Schoenberg Officer | Jun 10, 2025 | 5,162 | $38.04K | Jun 9, 2025 | Restricted Stock Units |
See a number that looks wrong?